Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method

Szeged University100 enrolled

Overview

Prospective assay for SARS-CoV-2 antibody detection indirectly by immunofluorescence: SARS-CoV2 IIF method

Sample preparation, serum separation by centrifugation * 100 µl of serum for standard SARS-CoV2 ELISA is used according to the instructions for use. * 100 µl of serum indirect immunofluorescent (IIF) method is used, the samples thus prepared analysis is performed under an automated microscope

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Sars-CoV2

Interventions

ImmunfluorescenceDIAGNOSTIC_TEST

Serum indirect immunofluorescent (IIF) method is used, analysis is performed under an automated microscope.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Person over 18 years of age * Signing a package leaflet and a informal consent * In the case of a positive group, confirmed by SARS-CoV2 qPCR Patient with COVID-19 or recovered individual. * In case of negative group by SARS-CoV2 qPCR test 2 negative in COVID-19 suffering individual Exclusion Criteria: * Refuses to sign the consent form

Locations (1)

University of Szeged, Albert Szent-Györgyi Health Center

Szeged, Hungary

RECRUITING

Outcomes

Primary Outcomes

Sensitivity of the method by SARS-CoV2 ELISA compared

Time frame: 8 months

Secondary Outcomes

Detectability of the antibodies IgA type against SARS-CoV2 virus

Detectability of the antibodies IgA type against SARS-CoV2 virus in the early stages of the disease.

Time frame: 8 months

Central Contacts

Katalin Burián, MD

CONTACT

+36 62 544 000 burian.katalin@med.u-szeged.hu

Dávid Pintér, Pharm. D.

CONTACT

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.